Selected research
Industry Research
Satralizumab Industry Research Report 2026
Market perspective
The global Satralizumab market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Satralizumab is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Satralizumab is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Satralizumab is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Satralizumab include Hoffmann La Roche, Genentech Inc. and CHUGAI PHARMACEUTICAL CO.,LTD., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Satralizumab market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Satralizumab Market by Company
Hoffmann La Roche
Genentech Inc.
CHUGAI PHARMACEUTICAL CO.,LTD.
Satralizumab Segment by Type
Solution
Injection
Satralizumab Segment by Application
Treating Neuromyelitis Optica
Prevention of Neuromyelitis Optica
Others
Satralizumab Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Satralizumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Satralizumab and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Satralizumab.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Satralizumab manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Satralizumab by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Satralizumab in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Solution
- Injection
Applications
- Treating Neuromyelitis Optica
- Prevention of Neuromyelitis Optica
- Others
Companies covered
- Hoffmann La Roche
- Genentech Inc.
- CHUGAI PHARMACEUTICAL CO.,LTD.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Satralizumab Market Size (2021-2032)
- 2.2.2 Global Satralizumab Sales (2021-2032)
- 2.2.3 Global Satralizumab Market Average Price (2021-2032)
- 2.3 Satralizumab by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Solution
- 2.3.3 Injection
- 2.4 Satralizumab by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Treating Neuromyelitis Optica
- 2.4.3 Prevention of Neuromyelitis Optica
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Satralizumab Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Satralizumab Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Satralizumab Revenue of Manufacturers (2021-2026)
- 3.4 Global Satralizumab Average Price by Manufacturers (2021-2026)
- 3.5 Global Satralizumab Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Satralizumab, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Satralizumab, Product Type & Application
- 3.8 Global Manufacturers of Satralizumab, Established Date
- 3.9 Global Satralizumab Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Hoffmann La Roche
- 4.1.1 Hoffmann La Roche Company Information
- 4.1.2 Hoffmann La Roche Business Overview
- 4.1.3 Hoffmann La Roche Satralizumab Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Hoffmann La Roche Satralizumab Product Portfolio
- 4.1.5 Hoffmann La Roche Recent Developments
- 4.2 Genentech Inc.
- 4.2.1 Genentech Inc. Company Information
- 4.2.2 Genentech Inc. Business Overview
- 4.2.3 Genentech Inc. Satralizumab Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Genentech Inc. Satralizumab Product Portfolio
- 4.2.5 Genentech Inc. Recent Developments
- 4.3 CHUGAI PHARMACEUTICAL CO.,LTD.
- 4.3.1 CHUGAI PHARMACEUTICAL CO.,LTD. Company Information
- 4.3.2 CHUGAI PHARMACEUTICAL CO.,LTD. Business Overview
- 4.3.3 CHUGAI PHARMACEUTICAL CO.,LTD. Satralizumab Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 CHUGAI PHARMACEUTICAL CO.,LTD. Satralizumab Product Portfolio
- 4.3.5 CHUGAI PHARMACEUTICAL CO.,LTD. Recent Developments
5 Global Satralizumab Market Scenario by Region
- 5.1 Global Satralizumab Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Satralizumab Sales by Region: 2021-2032
- 5.2.1 Global Satralizumab Sales by Region: 2021-2026
- 5.2.2 Global Satralizumab Sales by Region: 2027-2032
- 5.3 Global Satralizumab Revenue by Region: 2021-2032
- 5.3.1 Global Satralizumab Revenue by Region: 2021-2026
- 5.3.2 Global Satralizumab Revenue by Region: 2027-2032
- 5.4 North America Satralizumab Market Facts & Figures by Country
- 5.4.1 North America Satralizumab Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Satralizumab Sales by Country (2021-2032)
- 5.4.3 North America Satralizumab Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Satralizumab Market Facts & Figures by Country
- 5.5.1 Europe Satralizumab Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Satralizumab Sales by Country (2021-2032)
- 5.5.3 Europe Satralizumab Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Satralizumab Market Facts & Figures by Country
- 5.6.1 Asia Pacific Satralizumab Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Satralizumab Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Satralizumab Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Satralizumab Market Facts & Figures by Country
- 5.7.1 South America Satralizumab Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Satralizumab Sales by Country (2021-2032)
- 5.7.3 South America Satralizumab Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Satralizumab Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Satralizumab Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Satralizumab Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Satralizumab Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Satralizumab Sales by Type (2021-2032)
- 6.1.1 Global Satralizumab Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Satralizumab Sales Market Share by Type (2021-2032)
- 6.2 Global Satralizumab Revenue by Type (2021-2032)
- 6.2.1 Global Satralizumab Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Satralizumab Revenue Market Share by Type (2021-2032)
- 6.3 Global Satralizumab Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Satralizumab Sales by Application (2021-2032)
- 7.1.1 Global Satralizumab Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Satralizumab Sales Market Share by Application (2021-2032)
- 7.2 Global Satralizumab Revenue by Application (2021-2032)
- 7.2.1 Global Satralizumab Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Satralizumab Revenue Market Share by Application (2021-2032)
- 7.3 Global Satralizumab Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Satralizumab Value Chain Analysis
- 8.1.1 Satralizumab Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Satralizumab Production Mode & Process
- 8.2 Satralizumab Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Satralizumab Distributors
- 8.2.3 Satralizumab Customers
9 Global Satralizumab Analyzing Market Dynamics
- 9.1 Satralizumab Industry Trends
- 9.2 Satralizumab Industry Drivers
- 9.3 Satralizumab Industry Opportunities and Challenges
- 9.4 Satralizumab Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst